 | • レポートコード：MRC2304D103 • 出版社/出版日：Transparency Market Research / 2023年1月20日 • レポート形態：英文、PDF、213ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、肺がん治療の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、がん種類別（NSCLC、SCLC）分析、治療種類別（手術、放射線療法、標的療法、免疫療法、その他）分析、エンドユーザー別（病院、がん＆放射線治療センター、その他（専門クリニック））分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、Pfizer、AstraZeneca、Merck (MSD)、Bristol-Myers Squibb、Eli Lilly and Company、Boehringer Ingelheim、Novartis、Merck KGaA (EMD Serono)、AbbVie、Takeda、Astellas Pharma、F. Hoffmann-La Roche、GlaxoSmithKline、Johnson & Johnson、Sanofi、Amgenなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の肺がん治療市場規模：がん種類別 - NSCLCの市場規模 - SCLCの市場規模 ・世界の肺がん治療市場規模：治療種類別 - 手術の市場規模 - 放射線療法の市場規模 - 標的療法の市場規模 - 免疫療法の市場規模 - その他治療種類の市場規模 ・世界の肺がん治療市場規模：エンドユーザー別 - 病院における市場規模 - がん＆放射線治療センターにおける市場規模 - その他（専門クリニック）エンドユーザーにおける市場規模 ・世界の肺がん治療市場規模：地域別 - 北米の肺がん治療市場規模 - ヨーロッパの肺がん治療市場規模 - アジア太平洋の肺がん治療市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Lung Cancer Treatment Market – Scope of Report
TMR’s report on the global lung cancer treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global lung cancer treatment market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lung cancer treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global lung cancer treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer treatment market.
The report delves into the competitive landscape of the global lung cancer treatment market. Key players operating in the global lung cancer treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global lung cancer treatment market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market lung cancer treatment.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lung Cancer Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Lung Cancer Epidemiology
5.2. Pipeline Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Lung Cancer Treatment Market Analysis and Forecast, by Cancer Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cancer Type, 2017–2031
6.3.1. NSCLC
6.3.2. SCLC
6.4. Market Attractiveness Analysis, by Cancer Type
7. Global Lung Cancer Treatment Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment Type, 2017–2031
7.3.1. Surgery
7.3.2. Radiation Therapy
7.3.3. Targeted Therapy
7.3.4. Immunotherapy
7.3.5. Chemotherapy
7.3.6. Others (palliative care)
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Lung Cancer Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Cancer & Radiation Therapy Centers
8.3.3. Others (specialty clinics)
8.4. Market Attractiveness Analysis, by End-user
9. Global Lung Cancer Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lung Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Cancer Type, 2017–2031
10.2.1. NSCLC
10.2.2. SCLC
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Surgery
10.3.2. Radiation Therapy
10.3.3. Targeted Therapy
10.3.4. Immunotherapy
10.3.5. Chemotherapy
10.3.6. Others (palliative care)
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Cancer & Radiation Therapy Centers
10.4.3. Others (specialty clinics)
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Cancer Type
10.6.2. By Treatment Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Lung Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Cancer Type, 2017–2031
11.2.1. NSCLC
11.2.2. SCLC
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Surgery
11.3.2. Radiation Therapy
11.3.3. Targeted Therapy
11.3.4. Immunotherapy
11.3.5. Chemotherapy
11.3.6. Others (palliative care)
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Cancer & Radiation Therapy Centers
11.4.3. Others (specialty clinics)
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Cancer Type
11.6.2. By Treatment Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Lung Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Cancer Type, 2017–2031
12.2.1. NSCLC
12.2.2. SCLC
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Surgery
12.3.2. Radiation Therapy
12.3.3. Targeted Therapy
12.3.4. Immunotherapy
12.3.5. Chemotherapy
12.3.6. Others (palliative care)
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Cancer & Radiation Therapy Centers
12.4.3. Others (specialty clinics)
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Cancer Type
12.6.2. By Treatment Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Lung Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Cancer Type, 2017–2031
13.2.1. NSCLC
13.2.2. SCLC
13.3. Market Value Forecast, by Treatment Type, 2017–2031
13.3.1. Surgery
13.3.2. Radiation Therapy
13.3.3. Targeted Therapy
13.3.4. Immunotherapy
13.3.5. Chemotherapy
13.3.6. Others (palliative care)
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Cancer & Radiation Therapy Centers
13.4.3. Others (specialty clinics)
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Cancer Type
13.6.2. By Treatment Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Lung Cancer Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Cancer Type, 2017–2031
14.2.1. NSCLC
14.2.2. SCLC
14.3. Market Value Forecast, by Treatment Type, 2017–2031
14.3.1. Surgery
14.3.2. Radiation Therapy
14.3.3. Targeted Therapy
14.3.4. Immunotherapy
14.3.5. Chemotherapy
14.3.6. Others (palliative care)
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Cancer & Radiation Therapy Centers
14.4.3. Others (specialty clinics)
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Cancer Type
14.6.2. By Treatment Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Pfizer
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Cancer Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Cancer Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Merck (MSD)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Cancer Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Bristol-Myers Squibb
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Cancer Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Eli Lilly and Company
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Cancer Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Cancer Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.7. Novartis
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Cancer Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.8. Merck KGaA (EMD Serono)
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Cancer Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.9. AbbVie
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Cancer Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. Takeda
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Cancer Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.11. Astellas Pharma
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Cancer Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.12. F. Hoffmann-La Roche
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Cancer Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.13. GlaxoSmithKline
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Cancer Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.14. Johnson & Johnson
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Cancer Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.15. Sanofi
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Cancer Type Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.16. Amgen
15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.16.2. Cancer Type Portfolio
15.3.16.3. Financial Overview
15.3.16.4. SWOT Analysis
Table 01: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 02: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 03: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 07: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 08: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 11: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 12: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 15: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 16: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 19: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 20: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 23: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 24: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031